Peptides for PCOS: Emerging Research on Peptide-Based Approaches

Key Takeaways

• Compounds covered: GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide), kisspeptin, BPC-157
• Goal area: PCOS — metabolic features (insulin resistance, weight), HPG axis dysregulation (LH/FSH imbalance, anovulation), chronic low-grade inflammation
• Evidence range: Ranges from RCT-level evidence for GLP-1 agonists in PCOS metabolic endpoints to animal-only preclinical data (BPC-157 anti-inflammatory) to mechanistic/academic research (kisspeptin HPG axis dysregulation)
• Regulatory range: FDA-approved for other indications (GLP-1 agonists for type 2 diabetes and weight management); not FDA-approved for any indication (kisspeptin, BPC-157)
• Key biomarkers for PCOS: Fasting insulin, glucose, HbA1c, LH, FSH, LH:FSH ratio, total testosterone, free testosterone, SHBG, AMH, hs-CRP, prolactin
• As of April 2026: No peptide is FDA-approved for PCOS specifically. GLP-1 receptor agonists (semaglutide, tirzepatide) are FDA-approved for type 2 diabetes and weight management; their use in PCOS is off-label.
• Bottom line: Among the peptides covered here, GLP-1 receptor agonists have the most developed clinical evidence base for PCOS metabolic features but are not FDA-approved for PCOS; the evidence for other peptides in PCOS is preliminary or preclinical.

Understanding PCOS: The Biology

Polycystic ovary syndrome is a heterogeneous endocrine disorder characterized by a combination of features that are not equally present in every affected individual: hyperandrogenism (elevated male sex hormones), polycystic ovarian morphology on ultrasound, and ovulatory dysfunction. Clinical diagnosis typically requires two of these three, with other causes excluded.

The underlying pathophysiology involves at least three partially overlapping processes. First, insulin resistance is present in the majority of women with PCOS regardless of body weight — the metabolic dysfunction is not exclusively a consequence of obesity. Ni and colleagues, writing in Frontiers in Endocrinology in 2025, reviewed adipose-androgen crosstalk in PCOS, documenting how insulin resistance drives compensatory hyperinsulinemia that directly stimulates ovarian androgen production and reduces liver production of SHBG, further elevating free androgen levels. This insulin-androgen axis is one primary reason metabolic interventions have reproductive consequences in PCOS.

Second, the HPG axis is dysregulated. The normal pulsatile GnRH secretion required for coordinated LH and FSH release is altered in PCOS: GnRH pulse frequency is typically elevated, driving preferential LH secretion and producing the elevated LH:FSH ratio that is a clinical feature of the condition. Kauffman and colleagues, in a 2022 review in Frontiers in Neuroscience, established kisspeptin's central role in this dysregulation — specifically in the estrogen positive feedback mechanism required for the LH surge and ovulation, which is impaired in PCOS.

Third, chronic low-grade inflammation characterizes PCOS beyond its metabolic and endocrine features. Elevated hs-CRP, elevated inflammatory cytokines, and oxidative stress are consistently documented in PCOS populations. Wu and colleagues, writing in Frontiers in Immunology in 2025, reviewed PCOS's link to gynecological cancers, framing chronic low-grade inflammation and neurotransmitter-metabolism shifts as shared mechanistic threads connecting PCOS's reproductive and systemic features.

Peptides relevant to PCOS address subsets of this biology: GLP-1 receptor agonists primarily target the insulin-androgen axis; kisspeptin targets HPG axis regulation; BPC-157 targets inflammatory pathways in a non-specific way. No compound addresses all three simultaneously.

Peptides Studied for PCOS: A Quick Comparison

Important framing: No peptide is FDA-approved for the treatment of PCOS. The compounds discussed in this section are organized by the PCOS-adjacent mechanism they target, not by their status as PCOS treatments. GLP-1 receptor agonists have FDA approval for type 2 diabetes and chronic weight management (not PCOS); kisspeptin and BPC-157 have no FDA approval for any indication. Standard PCOS management — metformin, hormonal contraceptives, anti-androgens, and lifestyle intervention — remains the evidence-based first-line approach. Peptides are discussed here as emerging research topics, not as recommended PCOS treatments. Superpower does not prescribe any peptide for PCOS as an indication.

The following peptides have published evidence relevant to one or more aspects of PCOS biology. They are listed by strength of clinical evidence, from most-studied to least.

• Compound: Semaglutide (GLP-1 receptor agonist)
  Mechanism for PCOS: GLP-1 receptor agonism reducing insulin secretion demand, improving insulin sensitivity, promoting weight loss; reduced hyperinsulinemia lowers ovarian androgen production
  Evidence: Phase 3 RCTs for weight management (STEP program); multiple PCOS-specific studies and one RCT-level comparison (Liao et al., 2024) for PCOS metabolic endpoints
  FDA status: FDA-approved as Ozempic (type 2 diabetes) and Wegovy (weight management); use in PCOS is off-label. Off-label prescribing is permitted under the practice of medicine but has not been evaluated or endorsed by the FDA for this use
  SP availability: Superpower does not prescribe or dispense Ozempic or Wegovy (the branded FDA-approved products) and does not prescribe semaglutide for PCOS as an indication. Compounded semaglutide is not FDA-approved and is not the same medication as Ozempic or Wegovy. Because semaglutide is no longer on FDA's drug shortage list, a 503A pharmacy may compound semaglutide only where the prescribing provider documents a clinically significant difference for the specific patient that the commercially available FDA-approved formulations cannot meet (per FDCA § 353a(b)(1)(D)). Any availability through Superpower's licensed provider network is subject to that case-by-case clinical determination, state availability, and provider evaluation — it is not a general Superpower offering. Compounded semaglutide availability varies by state
  Route: Subcutaneous injection weekly
• Compound: Liraglutide (GLP-1 receptor agonist)
  Mechanism for PCOS: GLP-1 receptor agonism with metabolic effects similar to semaglutide; most PCOS-specific RCT data is for liraglutide
  Evidence: RCTs specifically in PCOS populations (Long et al., 2023; Pugliese et al., 2023); Phase 3 for weight management (non-PCOS populations)
  FDA status: FDA-approved as Victoza (type 2 diabetes) and Saxenda (weight management); PCOS use is off-label. Off-label prescribing is permitted under the practice of medicine but has not been evaluated or endorsed by the FDA for this use
  SP availability: Superpower does not prescribe or dispense Victoza or Saxenda and does not prescribe liraglutide for PCOS as an indication
  Route: Subcutaneous injection daily
• Compound: Tirzepatide (GIP/GLP-1 dual agonist)
  Mechanism for PCOS: Dual receptor agonism (GIP and GLP-1) with superior weight loss and metabolic effects; reduces hyperinsulinemia driving ovarian androgen excess
  Evidence: Phase 3 RCTs for weight management (SURMOUNT program); emerging PCOS-specific data; no completed PCOS-specific RCT published
  FDA status: FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (weight management and obstructive sleep apnea); PCOS use is off-label. Off-label prescribing is permitted under the practice of medicine but has not been evaluated or endorsed by the FDA for this use
  SP availability: Superpower does not prescribe or dispense Mounjaro or Zepbound (the branded FDA-approved products) and does not prescribe tirzepatide for PCOS as an indication. Compounded tirzepatide is not FDA-approved and is not the same medication as Mounjaro or Zepbound. Because tirzepatide is no longer on FDA's drug shortage list, a 503A pharmacy may compound tirzepatide only where the prescribing provider documents a clinically significant difference for the specific patient that the commercially available FDA-approved formulations cannot meet (per FDCA § 353a(b)(1)(D)). Any availability through Superpower's licensed provider network is subject to that case-by-case clinical determination, state availability, and provider evaluation — it is not a general Superpower offering. Compounded tirzepatide is not available in NY, NJ, CA, SC, AL, AR, or LA
  Route: Subcutaneous injection weekly
• Compound: Kisspeptin
  Mechanism for PCOS: KISS1R agonist; targets the HPG axis dysregulation (impaired estrogen positive feedback, elevated LH pulsatility) that underlies anovulation in PCOS
  Evidence: Mechanistic and preclinical evidence; academic clinical research in HPG axis protocols; limited PCOS-specific human data
  FDA status: Not FDA-approved for any indication; no USP monograph; not on the FDA 503A Bulks List — no FDA-endorsed 503A compounding pathway. Some state-licensed compounding pharmacies may dispense kisspeptin under patient-specific prescriptions, but this practice is outside the FDA-endorsed framework
  SP availability: Not available through Superpower
  Route: Subcutaneous injection
• Compound: BPC-157
  Mechanism for PCOS: Cytoprotective and anti-inflammatory pentadecapeptide; proposed relevance to PCOS chronic low-grade inflammation via anti-inflammatory pathway modulation
  Evidence: Animal studies for anti-inflammatory properties; no human PCOS trial data
  FDA status: Not FDA-approved for any indication; no USP monograph; not on the FDA 503A Bulks List; not eligible for compounding under Section 503A. Previously listed as an interim Category 2 bulk drug substance; FDA removed BPC-157 from the Category 2 list effective April 22, 2026 — removal does not equal promotion to Category 1, and BPC-157 remains ineligible for 503A compounding
  SP availability: Not legally available under the current FDA framework; Superpower does not offer this compound
  Route: Subcutaneous injection or oral (research settings only)

Compounds without a clear FDA-endorsed pathway (kisspeptin, BPC-157) have not completed the clinical trial process required for FDA approval for any indication. Their inclusion here is for educational context only. Kisspeptin may be dispensed by some state-licensed compounding pharmacies under patient-specific prescriptions outside FDA's endorsed framework; BPC-157 is not eligible for 503A compounding.

Peptides Studied for PCOS: Individual Profiles

PCOS involves overlapping metabolic, endocrine, and inflammatory pathways, and the compounds below address different subsets of these. Evidence levels and regulatory statuses are distinct for each compound.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide)

GLP-1 receptor agonists are the peptide class with the most clinically relevant evidence for PCOS. Their mechanism of action for PCOS metabolic features is indirect: by slowing gastric emptying, stimulating glucose-dependent insulin secretion, and activating central appetite-suppressing circuits, they reduce caloric intake and produce weight loss. In women with PCOS, weight loss has been associated with reductions in hyperinsulinemia and corresponding reductions in ovarian androgen stimulation; observational and small RCT data suggest this can correspond to improvements in cycle regularity and ovulatory function, though the evidence for these reproductive endpoints is less robust than for the metabolic ones. Yang and colleagues, reviewing weight-loss strategies for PCOS in Current Obesity Reports in 2025, reported improvements in PCOS hormonal and metabolic outcomes — including hyperandrogenism and menstrual regularity — with GLP-1-mediated weight loss, particularly when combined with metformin.

Liao and colleagues published a study in Endocrine in 2024 comparing GLP-1 receptor agonist therapy versus combined oral contraceptive plus metformin in overweight PCOS patients, characterizing differences in plasma proteomics that illuminate distinct metabolic mechanisms. Long and colleagues published an RCT in Gynecological Endocrinology in 2023 demonstrating significant weight loss and metabolic improvement with low-dose liraglutide combined with metformin in Chinese women with PCOS. Pugliese and colleagues, in a 2023 review in the Journal of Endocrinological Investigation, examined whether liraglutide's effects in PCOS extend beyond body weight reduction. [RCT-level evidence for GLP-1 class in PCOS metabolic endpoints; no FDA-approved PCOS indication]

Semaglutide, liraglutide, and tirzepatide are FDA-approved for type 2 diabetes and chronic weight management — not for PCOS. GLP-1 receptor agonists are FDA-approved for chronic weight management in patients meeting BMI criteria (BMI ≥30, or ≥27 with a weight-related comorbidity). A PCOS patient meeting these criteria can receive GLP-1 therapy for the approved weight-management indication; any PCOS-specific hormonal or reproductive improvements that may occur are considered collateral effects of the on-label weight-management use and are not independently supported by FDA-evaluated PCOS endpoints. Prescribing GLP-1 therapy specifically for PCOS (in a patient who does not meet the weight-management criteria) would be off-label. Prescribing GLP-1 therapy specifically because a patient has PCOS — even where BMI criteria are also met — would approach an off-label indication framework that Superpower does not operate under. Superpower does not prescribe GLP-1 therapy for PCOS as an indication. A provider evaluation for the approved indications (type 2 diabetes, chronic weight management) would assess BMI, metabolic status, and concurrent medications before determining appropriateness.

Kisspeptin for HPG axis dysregulation in PCOS

PCOS's characteristic HPG axis disruption — elevated GnRH pulse frequency, elevated LH, relative FSH suppression, and impaired estrogen positive feedback — involves kisspeptin circuitry. Bhattarai and colleagues, in a 2022 study in Frontiers in Endocrinology, examined GnRH neuron neurotransmission in a letrozole-induced PCOS animal model, documenting disrupted kisspeptin signaling as a contributor to the elevated LH pulsatility pattern. Rheza and colleagues, writing in the Open Veterinary Journal in 2023, studied serum kisspeptin levels and ovarian kisspeptin expression in a PCOS rat model, finding patterns consistent with dysregulated kisspeptin signaling at the ovarian level. Salmeri and colleagues, in a 2024 review in Reviews in Endocrine and Metabolic Disorders, reviewed the kisspeptin system across female reproductive disorders including PCOS, positioning kisspeptin as an emerging therapeutic target. [Preclinical and mechanistic evidence; limited PCOS-specific human clinical data]

Kisspeptin is not FDA-approved for any indication. It has no USP monograph, is not on the FDA 503A Bulks List, and has no FDA-endorsed 503A compounding pathway. Some state-licensed compounding pharmacies may dispense kisspeptin under patient-specific prescriptions, but this practice is outside the FDA-endorsed framework. It is not available through Superpower. The clinical research on kisspeptin in PCOS is early-stage; the published human data is primarily mechanistic and comes from academic research programs, not from commercial PCOS treatment trials. Xu and colleagues, in a 2026 review in Comprehensive Physiology focused on perimenopausal reproductive physiology, characterized kisspeptin neurons as an integrative hub across the HPO-HPT-HPA axes — a framework that may be relevant by extension for PCOS patients with thyroid or HPA axis comorbidities, though the review does not directly study PCOS.

BPC-157 for PCOS-associated inflammation

Chronic low-grade inflammation is documented in PCOS across multiple biomarkers. Mirjalili and colleagues, studying metformin's effects on inflammatory pathways in obese PCOS patients in PLOS One in 2025, characterized metformin's modulation of inflammasome-regulating microRNAs and related inflammatory gene expression (IL-1β, IL-18, caspase-1, NLRP3) in obese PCOS patients and identified these as therapeutic targets alongside insulin sensitivity. BPC-157, which has preclinical anti-inflammatory and cytoprotective evidence, has been proposed in this context based on mechanism, not on PCOS-specific data. Seiwerth and colleagues' 2021 review in Frontiers in Pharmacology documented BPC-157's wound-healing and anti-inflammatory properties across animal models, but no human study in PCOS has been conducted. [Animal studies; no human PCOS data]

This compound has not been approved by the FDA for any medical use. BPC-157 has no USP monograph, is not on the FDA 503A Bulks List, and is not eligible for compounding under Section 503A. FDA removed BPC-157 from the interim Category 2 bulk drug substances list effective April 22, 2026; removal did not place the compound on Category 1, and BPC-157 remains ineligible for 503A compounding. It is not legally available under the current FDA framework; Superpower does not offer this compound. Inclusion here is for educational context about the mechanistic rationale only.

Regulatory Status at a Glance

As of April 2026, the compounds discussed in this article carry different regulatory statuses. PCOS-specific use is off-label for all of them.

• Semaglutide: FDA-approved as Ozempic for type 2 diabetes and as Wegovy for chronic weight management in adults with BMI ≥30 or ≥27 with a weight-related comorbidity. PCOS-specific use is off-label.
• Liraglutide: FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. PCOS-specific use is off-label.
• Tirzepatide: FDA-approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea. PCOS-specific use is off-label.
• Kisspeptin: Not FDA-approved for any indication; no USP monograph; not on the FDA 503A Bulks List — no FDA-endorsed 503A compounding pathway. Some state-licensed compounding pharmacies may dispense kisspeptin under patient-specific prescriptions outside FDA's formally approved pathway. Not available through Superpower.
• BPC-157: Not FDA-approved for any indication; no USP monograph; not on the FDA 503A Bulks List; not eligible for 503A compounding. Previously listed as an interim Category 2 bulk drug substance; FDA removed BPC-157 from the Category 2 list effective April 22, 2026 — removal does not equal promotion to Category 1. Not legally available in the US; not offered by Superpower.

Compounds without a 503A-eligibility pathway are not legally available to prescribe, compound, or sell for human use in the US. Their presence in this article is for educational context only and does not constitute an offer, recommendation, or endorsement of use.

Considerations When Comparing Peptides for PCOS

PCOS is heterogeneous: two women with the same diagnosis may have very different metabolic profiles, androgen levels, and HPG axis patterns. The compound or combination of approaches relevant to one individual may be inappropriate for another.

Direct comparison between GLP-1 agonists and kisspeptin for PCOS is not straightforward. They target different pathways and have been studied in different contexts. Inferring relative effectiveness from separate trials is methodologically unreliable.

Metabolic PCOS versus HPG-dominant PCOS: Women with PCOS who have prominent insulin resistance, elevated fasting insulin, and weight above the reference range have the strongest evidence base for GLP-1 agonist consideration. Women with PCOS whose primary manifestation is HPG axis dysregulation — irregular LH/FSH, anovulation, and relatively normal insulin — may be better candidates for HPG-axis-targeted approaches, though kisspeptin's evidence for this is still early-stage.

Standard-of-care integration: Any peptide approach for PCOS would be evaluated by a provider in the context of existing management: metformin, hormonal contraceptives, anti-androgens, and lifestyle interventions are the established evidence base. Sridharan and colleagues, in a 2025 review in Diabetology and Metabolic Syndrome, positioned GLP-1 receptor agonists as expanding therapeutic options within PCOS management, not as replacing established approaches. Peptide options are best framed as potential adjuncts evaluated alongside — not instead of — existing PCOS management.

Weight status and comorbidity: GLP-1 receptor agonists have FDA approval for weight management in patients meeting BMI criteria. Women with PCOS who also meet those criteria have a clearer access pathway to GLP-1 agonists than those whose PCOS is not accompanied by weight-related comorbidities.

Reproductive intent: For women with PCOS who are seeking conception, the evidence hierarchy shifts. GLP-1 agonists are typically discontinued before conception given the absence of safety data in early pregnancy. Kisspeptin's research in ovulation induction is being developed but is not an established clinical pathway. A reproductive endocrinologist evaluation is appropriate for PCOS management in the context of fertility goals.

This is not an exhaustive list of clinical considerations. A licensed provider will evaluate your full health history, current medications, and baseline lab results before recommending any compound.

Safety Considerations

Safety profiles differ substantially across this list. GLP-1 receptor agonists have the most characterized safety profiles because of their Phase 3 trial programs and widespread clinical use.

For GLP-1 receptor agonists in women with PCOS: the most common adverse effects are gastrointestinal (nausea, vomiting, diarrhea, constipation), which are dose-dependent and typically decrease with titration. GLP-1 agonists are generally not used during pregnancy — they carry a pregnancy risk category requiring discontinuation before conception. Women with PCOS exploring GLP-1 therapy who are also managing fertility goals should discuss timing and transition planning with their provider explicitly.

For kisspeptin: the published human safety data comes from academic research protocols conducted in HPG axis studies. There is no Phase 3 safety data. Long-term safety in PCOS populations specifically has not been studied.

For BPC-157: as a restricted compound with primarily animal-study data, the human safety profile has not been characterized. Accessing it through unregulated channels adds contamination and dosing uncertainty risks.

Contraindications relevant to the compounds discussed in this article (these are the approved-label contraindications for GLP-1 receptor agonists, not PCOS-specific contraindications):

• Pregnancy or planned pregnancy (near-term) — GLP-1 agonists require discontinuation before conception; kisspeptin's reproductive effects require provider evaluation
• Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — contraindication for GLP-1 agonists per approved labeling
• Pancreatitis history — GLP-1 agonists have a labeled caution for pancreatitis risk
• History of severe hypoglycemia or diabetic ketoacidosis — provider evaluation required before initiating any compound affecting insulin and glucose metabolism

For compound-specific side effect profiles, consult the FDA-approved prescribing information for each GLP-1 receptor agonist at dailymed.nlm.nih.gov.

What to Test Before Starting Peptides for PCOS

Regardless of which compound a provider discusses, baseline biomarker testing establishes a measurable starting point. Without it, there is no objective way to assess whether a compound is producing the expected physiological changes — or whether those changes are beneficial.

• Fasting insulin: The most direct measure of insulin resistance severity. Testing fasting insulin before starting any GLP-1 agonist establishes the degree of hyperinsulinemia driving androgen excess and metabolic dysfunction in PCOS. It provides the reference point against which improvement can be measured.
• HbA1c: A 3-month average of blood glucose reflecting longer-term insulin sensitivity. A baseline HbA1c establishes whether glucose management is already a concern and contextualizes the degree of metabolic dysfunction present.
• Glucose (fasting): Pairs with fasting insulin to calculate HOMA-IR (a commonly used insulin resistance index). Testing fasting glucose is standard in any metabolic baseline panel for PCOS.
• LH and FSH: The LH:FSH ratio is a defining clinical feature of PCOS (typically elevated above 2:1). Testing LH and FSH characterizes the HPG axis dysregulation pattern before any HPG-axis-relevant intervention is considered.
• Total and free testosterone: Hyperandrogenism is a clinical criterion of PCOS. Baseline total testosterone and free testosterone document androgen excess level and track response to insulin-sensitizing interventions that reduce ovarian androgen production.
• SHBG: Hyperinsulinemia suppresses hepatic SHBG production, increasing free androgen bioavailability. A baseline SHBG characterizes the androgen-binding context and tracks as insulin sensitivity improves.
• hs-CRP: Chronic low-grade inflammation is documented across PCOS populations. A baseline hs-CRP characterizes inflammatory burden before any intervention.
• AMH (anti-Müllerian hormone): Elevated AMH is associated with the polycystic ovarian morphology of PCOS and provides context for ovarian reserve and follicular dynamics. Testing AMH at baseline is increasingly part of standard PCOS evaluation.

Fasting insulin, HbA1c, glucose, LH, FSH, testosterone, and SHBG together characterize the three pathophysiological axes of PCOS — metabolic, androgenic, and HPG — before any peptide intervention is introduced. Testing at baseline and at 3–6 months provides the timeline needed to assess whether any intervention is producing the expected biological changes. The blood sugar and insulin sensitivity biomarker guide covers the metabolic markers in this panel.

How to Access These Peptides Safely

GLP-1 receptor agonists — semaglutide, liraglutide, tirzepatide — are FDA-approved prescription medications for type 2 diabetes and chronic weight management, obtained through a licensed healthcare provider and pharmacy for those approved indications. PCOS use is off-label; a provider may discuss the clinical rationale, monitor for adverse effects, and evaluate concurrent medications (including metformin, hormonal contraceptives, and anti-androgens) before prescribing for an on-label indication. Superpower does not prescribe GLP-1 therapy for PCOS as an indication and does not dispense the FDA-approved branded products (Ozempic, Wegovy, Victoza, Saxenda, Mounjaro, Zepbound). Where a patient also meets the BMI-based criteria for the approved chronic weight-management indication, a provider may evaluate GLP-1 therapy for that on-label indication separately from PCOS considerations.

Kisspeptin has no FDA-endorsed 503A compounding pathway (no USP monograph, not on the 503A Bulks List). Some state-licensed compounding pharmacies may dispense it under patient-specific prescriptions outside the FDA-endorsed framework. It is not available through Superpower.

BPC-157 is not eligible for compounding under Section 503A (no USP monograph, not on the 503A Bulks List; removed from interim Category 2 effective April 22, 2026 without conferring Category 1 status). Superpower does not offer BPC-157.

Self-directed use of any compound for PCOS — without provider evaluation, baseline labs, and monitoring — removes the clinical framework that makes any intervention's benefit assessable and manageable.

Understanding Your Baseline

PCOS involves multiple measurable pathophysiological processes — insulin resistance, HPG axis dysregulation, androgen excess, and chronic inflammation — each of which corresponds to specific biomarkers that can be measured before any peptide conversation begins. Knowing which processes are measurably prominent in a specific individual transforms a general question about "peptides for PCOS" into a focused clinical question: which mechanism corresponds to what the labs actually show?

That principle — test first, then decide — is central to Superpower's approach to preventive health. Whether the conversation with a provider leads to a GLP-1 receptor agonist, a kisspeptin protocol, a lifestyle-first approach, or standard PCOS pharmacotherapy, the starting point is the same: objective biomarker data that reflects what is actually happening in the metabolism and HPG axis.

IMPORTANT SAFETY INFORMATION

Semaglutide is FDA-approved as Ozempic for the treatment of type 2 diabetes and as Wegovy for chronic weight management. Its use in PCOS is off-label. Off-label prescribing is permitted under the practice of medicine but has not been evaluated or endorsed by the FDA for this use. Semaglutide is a prescription medication. Contraindications: personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, known hypersensitivity to semaglutide. Warnings: thyroid C-cell tumors in rodents (clinical significance in humans under ongoing evaluation); pancreatitis; hypoglycemia when combined with insulin or insulin secretagogues; acute kidney injury; serious hypersensitivity reactions. Common side effects: nausea, vomiting, diarrhea, constipation, abdominal pain. Full prescribing information at dailymed.nlm.nih.gov.

Liraglutide is FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. PCOS use is off-label. Contraindications and warnings are similar in class to semaglutide (see above). Full prescribing information at dailymed.nlm.nih.gov.

Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea. PCOS use is off-label. Class contraindications apply (see semaglutide above). Full prescribing information at dailymed.nlm.nih.gov.

Kisspeptin is not FDA-approved for any indication. It has no USP monograph, is not on the FDA 503A Bulks List, and has no FDA-endorsed 503A compounding pathway. Some state-licensed compounding pharmacies may dispense kisspeptin under patient-specific prescriptions, but this practice is outside the FDA-endorsed framework. It is not prescribed, compounded, or dispensed through Superpower. Safety and efficacy for PCOS management have not been established through adequate and well-controlled clinical trials. Research on kisspeptin in PCOS is primarily from preclinical and mechanistic studies. This page is for educational purposes only.

BPC-157 is not approved by the FDA for any medical use. It has no USP monograph, is not on the FDA 503A Bulks List, and is not eligible for compounding under Section 503A. FDA removed BPC-157 from the interim Category 2 bulk drug substances list effective April 22, 2026; removal did not place the compound on Category 1, and BPC-157 remains ineligible for 503A compounding. Research is limited primarily to animal studies. Its safety, efficacy, dosing, and long-term effects in humans have not been established. BPC-157 is not prescribed, compounded, or dispensed through Superpower.

Full FDA-approved prescribing information at dailymed.nlm.nih.gov.